Loading…

Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): Effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients

Background: Previous evidence indicates that pioglitazone may improve dyslipidemia in patients with Type 2 diabetes mellitus (T2DM). Aim: The primary objective of this study was to evaluate the effect of either pioglitazone or placebo with metformin on levels of serum HDL cholesterol (HDL-C) in pati...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endocrinological investigation 2013-09, Vol.36 (8), p.606-616
Main Authors: Genovese, S., Passaro, A., Brunetti, P., Comaschi, M., Cucinotta, D., Egan, C. G., Chinea, B., Bravi, F., Di Pietro, C.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Previous evidence indicates that pioglitazone may improve dyslipidemia in patients with Type 2 diabetes mellitus (T2DM). Aim: The primary objective of this study was to evaluate the effect of either pioglitazone or placebo with metformin on levels of serum HDL cholesterol (HDL-C) in patients with T2DM. A secondary objective evaluated changes in metabolic syndrome (MS)-specific parameters. Subjects and Methods: This multicenter, double-blind, randomized study was performed in patients with T2DM treated with metformin and hemoglobin A1c (HbA 1c ) levels between 6–8%, central obesity and reduced HDL-C. MS was evaluated from global changes in parameter values and expressed as a single factorial score following multivariate analysis of each parameter. 213 patients (110 in the pioglitazone group and 103 in the placebo group) were available for intention-to-treat analysis. Results: Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6.3 mg/dl vs 3.0 mg/dl; p
ISSN:0391-4097
1720-8386
DOI:10.3275/8895